Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 in Relapsed/Refractory Classical Hodgkin Lymphoma
CTR20190097Phase 2Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in Hodgkin lymphoma (HL), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Jan 2019; status: terminated.
02
Drugs
benmelstobart
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on CTR20190097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190097.